Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome

A meta-analysis

Xian-Ling Zeng, MD, Ya-Fei Zhang, MD, Quan Tian, PhD, Yan Xue, PhD, Rui-Fang An, PhD

Abstract

Aim: The aim of the study is to evaluate the effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome (PCOS).

Methods: We searched electronic databases and bibliographies of relevant papers to identify studies comparing the pregnancy outcomes in the metformin group with those in the placebo or blank control group. Then, we did this meta-analysis based on the PRISMA guidelines. The primary outcomes included early pregnancy loss (EPL), preterm delivery, term delivery, and gestational diabetes mellitus (GDM). Secondary outcomes included pregnancy-induced hypertension (PIH), intrauterine growth restriction (IUGR), fetal malformation, vaginal delivery (VD), cesarean section (CS), and metformin’s side effects, such as nausea or gastrointestinal discomfort. Certainly, data about neonatal death and macrosomia were analyzed if data available.

Results: Finally, 13 studies including 5 randomized controlled trials (RCT) and 8 cohort studies involving 1606 pregnant women with PCOS were analyzed. The pooled OR of EPL was 0.19 with obvious statistical significance, manifesting that metformin help to lower the rate of EPL (95% CI 0.12–0.28, P < 0.00001). Simultaneously, metformin showed the advantage of reducing the prevalence of preterm delivery (OR 0.37, 95% CI 0.20–0.68, P = 0.002). In addition, metformin could promote term delivery greatly and the pooled OR was 5.23 with sharp statistical difference (95% CI 3.12–8.75, P < 0.00001).

Conclusion: Metformin treatment in women with PCOS throughout pregnancy could increase the possibility of term delivery, VD and reduce the risk of EPL, preterm labor, pregnancy complications such as GDM and PIH, with no serious side effects. Moreover, metformin was not teratogenic based on the limited data. So we may recommend metformin treatment for women with PCOS during the whole pregnancy period for it is quite beneficial and safe for both mothers and babies.

Abbreviations: CI = confidence interval, CS = cesarean section, EPL = early pregnancy loss, GDM = gestational diabetes mellitus, IUGR = intrauterine growth restriction, OR = odds ratio, PCOS = polycystic ovary syndrome, PIH = pregnancy-induced hypertension, RCT = randomized controlled trial, VD = vaginal delivery.

Keywords: early pregnancy loss, gestational diabetes mellitus, metformin, polycystic ovary syndrome, pregnancy outcomes

1. Introduction

Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility worldwide. Many women with PCOS have difficulty in conceiving naturally. Even if patients with PCOS are lucky enough to become pregnant, yet they still have to face the distressing conditions of increased risk of early pregnancy loss (EPL), which is 5-fold higher than for non-PCOS women.[1–3] Additionally, women with PCOS are at increased risk of developing pregnancy complications, such as gestational diabetes mellitus (GDM) and preeclampsia, which may occur independent of obesity. The babies whose mothers are patients with PCOS are also at great risk of neonatal complications such as premature delivery, prenatal morbidity, and admission to an neonatal intensive care unit.[4]

The etiology of this condition in women with PCOS is still uncertain. Some scholars contended that hyperinsulinemic resistance could be an independent risk factor due to its adverse effects on endometrial function and implantation environment. Furthermore, some studies deemed hyperinsulinemic resistance aggravate such a destructive condition through increasing androgen concentration.[4,5] Fortunately, the insulin-sensitizer, like metformin (1,1-dimethylbiguanide hydrochloride), showed the ability to reduce androgen concentration and regain ovarian ovulatory cycles[6,7] and was assumed to have a linkage to the dramatic reduction in the incidence of EPL.[8]

However, the use of metformin was strictly limited during pregnancy because of its potential teratogenic effects. In Australia, metformin has been classified by the Therapeutic Goods Administration as Category C. One study[9] suggested metformin had no adverse effects on children although it can pass through the placenta, particularly during delivery. Marques et al[10] stated there was no higher risk of maternal or neonatal...
complications when metformin was employed as an oral hypoglycaemic agent. On the contrary, another study revealed metformin treatment from the first trimester to delivery did not reduce pregnancy complications in women with PCOS. Therefore, the issue of whether metformin treatment would help to achieve a better final outcome for both mothers and babies remains unclear.

Now that our aim is to investigate the effects of metformin on pregnancy outcomes in women with PCOS, the objects in control groups should also be pregnant women with PCOS. Although several reviews have focused on the use of metformin on pregnant women with PCOS, yet they included studies which had no control groups or had an inappropriate control group. For example, 1 review had studies in which the control group was made up of healthy pregnant women or without control groups. Another review included a study in which the control group was composed of healthy pregnant women. A third review recruited 1 study without a control group and another study in which the control group was constituted by non-PCOS pregnant women. There was also a research involving 1 study with non-PCOS pregnant women in the control group and 1 study composed of randomly selected obstetric women.

Thus, considering this controversy, we decided to conduct a meta-analysis of studies about pregnant women with PCOS comparing the effects of metformin on pregnancy outcomes between metformin groups and placebo or blank groups. The primary outcomes included EPL, preterm delivery, term delivery, GDM. Secondary outcomes included pregnancy-induced hypertension (PIH), intrauterine growth restriction (IUGR), fetal malformation, vaginal delivery (VD), cesarean section (CS), and metformin’s side-effects, such as nausea or gastrointestinal discomfort. Certainly, data about neonatal death and macrosomia were analyzed if data available.

2. Materials and methods

2.1. Search strategy

We searched PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), ClinicalTrials.gov, the Cochrane Library and bibliographies of relevant papers published from January 2000 to September 2015, without language limitations, using the keywords and combinations of the following search terms “metformin” and “polycystic ovary syndrome/PCOS” and “pregnancy outcomes” or “pregnancy complications” or “reproductive outcomes” or “effects.”. Then, we did this meta-analysis based on the PRISMA guidelines.

2.2. Study selection criteria

All published articles about women with PCOS became pregnant spontaneously or when using metformin and continued to use metformin throughout the pregnancy period or at least during the first trimester were included. Simultaneously, it is indispensable to have a placebo or blank control group of women with PCOS. Moreover, the outcomes should include primary outcomes or secondary outcomes.

2.3. Study exclusion criteria

Studies without control groups were certainly excluded. And studies with healthy obstetric women or non-PCOS women in control groups were also excluded. Abstracts, reviews, and pilot studies were excluded because of the absence of details concerning study methods and results. Studies were surely ineligible if information on any of the outcomes of focus was not provided.

2.4. Data extraction, synthesis, and analysis

The study would not be reviewed if the abstract could not meet the selection criteria. Two reviewers (Zeng and Zhang) reviewed the recruited articles independently, and then decided on whether the article was suited for our meta-analysis. As to disagreements, consensus was arrived through discussing with a third reviewer (Tian). Finally, the data for outcomes were extracted by 2 reviewers independently.

We relied on the program “Review Manager 5.2” to conduct the statistical analysis. The summary odds ratio (OR) and 95% confidence interval (CI) for dichotomous variables was calculated using Mantel–Haenszel and fixed/random effects mode. The F statistic was used to test statistical heterogeneity between studies. A random effects model was applied if the heterogeneity was substantial ($I^2$ greater than 25%). And a subgroup analysis was conducted if necessary. The OR was calculated as the ratio of events using metformin over those using placebo or stopping using metformin. The results were considered to be of statistical significance on condition that the 95% CI did not encompass 1.0 for OR and the P value was <0.05. Simple chi-square test was performed to test the homogeneity among the pooled results. Based on the modified scoring system, we conducted the methodological quality assessment of the studies. Points were awarded on the basis of the quality of randomization, blinding, and follow-up. In addition, we also assessed concealment of allocation. The potential publication bias was examined using the funnel plot.

2.5. Ethical approval

The ethical approval was not necessary for the reason that our study was a meta-analysis belonging to secondary analysis.

3. Results

This research generated 408 articles totally and 379 articles were excluded undoubtedly after screening the titles and abstracts. Among the remaining 29 articles, 16 articles were excluded because of uninteresting controls, unavailable data, and a pilot study. The remaining articles including 5 randomized controlled trials (RCT) and 8 cohort studies were reviewed carefully. Finally, 13 studies involving 1606 pregnant women with PCOS were included (Fig. 1).

The characteristics of the included studies were showed in Table 1. The largest number of objectives was 360, almost 9-fold of the smallest number and only 3 studies had the number of objectives more than 200. Seven studies including 5 RCTs and 2 cohort studies had placebo or blank controls. However, in control groups of 5 studies, metformin was discontinued once the pregnancy was confirmed by positive serum β-human chorionic gonadotropin or ultrasonography. Only 1 study stopped metformin treatment at the 8th gestational week. To define PCOS, 11 studies used the revised 2003 consensus diagnostic criteria, 1 study applied the 1990 National Institutes of Health criteria and another study employed the Rotterdam criteria.
As to the quality assessment (Table 2), all 5 RCTs described methods to generate randomization, allocation concealment, methods of blinding and follow-up status, gaining a total score of 7 to 8 points. Apart from 2 RCTs done in single center, the 3 left were done in multicenters. In addition to 1 study with a follow-up rate of 80.94%, the others all achieved perfect satisfaction. The included 8 cohort studies were composed of 7 prospective studies and 1 retrospective study.

Six studies offered the rate of EPL and the pooled OR was 0.19 with obvious statistical difference (95% CI 0.12–0.28, $P<0.00001$) (Fig. 2). For preterm delivery, metformin showed the advantage of reducing the prevalence, and the statistically significant difference was observed (OR 0.37, 95% CI 0.20–0.68, $P=0.002$) (Fig. 3). In addition, metformin could promote term delivery greatly and the pooled OR was 5.23 with sharp statistical difference (95% CI 3.12–8.75, $P<0.00001$) (Fig. 4). Moreover, the meta-analysis of 8 studies showed metformin tended to decrease the frequency of GDM when it was continued throughout the pregnancy period, but there was remarkable heterogeneity (OR 0.02, 95% CI 0.14–0.87, $I^2=84\%$). So we performed a subgroup analysis of GDM. When we included RCTs only, metformin showed no priority in lowering the rate of GDM and the OR was 1.23 (95% CI 0.71–2.12, $P=0.46$, $I^2=0\%$). While we excluded RCTs, the pooled OR of the remaining 5 prospective studies was 0.15, with obvious statistical difference and smaller heterogeneity (95% CI 0.07–0.33, $P<0.00001$, $I^2=55\%$) (Fig. 5).

As to the secondary outcomes, metformin could help to lessen the occurrence of PIH apparently with evident statistical difference ($P<0.00001$). Simultaneously, the modes of labor were analyzed in details. Metformin was likely to accelerate the rate of VD and cut down the rate of CS, but no statistical difference was found (both $P=0.48$). Furthermore, researchers also performed a comparison of fetal malformation between infants whose mothers persisted in using metformin throughout pregnancy and those had no history of metformin treatment or stopped use of metformin after conception. Total 3 studies provided data and the pooled OR was 1.11 without achieving any statistical significance ($P=0.88$). When it came to baby’s weight, metformin reduced the rate of IUGR with obvious statistical difference ($P<0.00001$). Only 1 study[23] provided data on macrosomia and neonatal death, and the rate of macrosomia was 0 in the metformin group versus 12.5% in the control group and the latter was 0 in the metformin group versus 3.13% in the control group. Finally, it is high time to mention the side effects of metformin, such as nausea or gastrointestinal discomfort, but no statistically significant difference was witnessed (OR 1.28, 95% CI 0.37–4.37, $P=0.70$) (Table 3).

To evaluate the possibly existing publication bias, the funnel plot was demonstrated to find no evidence of asymmetry, suggesting that publication bias was not present (Fig. 6).

4. Discussion

There is emerging evidence that the primary pathogenesis of PCOS is associated with increased insulin resistance. Insulin sensitizers, such as metformin, may be beneficial in dealing with PCOS[4,31]. There are uncertainties about when metformin should be discontinued and what dose of metformin should be given. Some authorities recommended discontinuation of metformin once the pregnancy was confirmed because of concerns about harms to the fetus.[32] However, the evidence that metformin is nonteratogenic has been obtained.[41] In this meta-analysis, 12 studies continued metformin use throughout pregnancy period and 1 study continued metformin use till 12th gestational week.[32] Eight studies applied the dose of 1000 to 2000mg daily, 3 studies adopted the dose according to BMI, 1 study took the dose of 2.550 mg daily, and 1 study did not report the dose.

Ben-Haroush et al argued women with PCOS had a higher miscarriage rate than the general female population, so they recommend persistent use of metformin during the first trimester expecting to decrease the incidence of EPL.[13] Ehrmann[34] also thought PCOS was associated with poorer pregnancy outcomes and metformin treatment in pregnant women with PCOS may reduce pregnancy complications. A retrospective study deemed metformin administration during pregnancy reduced the risk of pregnancy loss in the first trimester in women with PCOS.[28] A prospective study also suggested administration of metformin throughout pregnancy to women with PCOS was associated with a marked reduction in the rate of EPL.[25] Our findings indicated that metformin helped to reduce the rates of EPL and preterm delivery, which were consistent with previous studies.

Although it is more often for women with PCOS to develop GDM than healthy women,[15] yet metformin was associated with a 10-fold reduction in the rate of GDM in women with PCOS.[24] Many studies revealed metformin also seemed to reduce the incidence of GDM, pre-eclampsia, and fetal macrosomia.[24,36–38] Khattab et al[27] held metformin was a promising medication for the prevention or reduction of the
| Study                  | Period                     | Location | Study type | Inclusion criteria                                                                 | Exclusion criteria                                                                 | Metformin (n)                                                                 | Comparator (n) | Diagnostic criteria of PCOS                      |
|-----------------------|----------------------------|----------|------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------|-------------------------------------------------|
| Vanky et al[19]       | October 2000–March 2003    | Norway   | RCT        | Women who were 18–40 y and diagnosed with PCOS before conception. A singleton viable fetus was judged by ultrasonography at gestational age between 5 and 12 wks. | Women who had liver disease, creatinine > 130 mmol/L, alcohol abuse or previously known DM. And women whose fasting plasma glucose > 5.6 mmol/L, or treatment with oral glucocorticoids or use of drugs known to interfere with metformin. | Metformin (metformin hydrochloride, Metformin®; Weifa AS, Norway) was given 850 mg once daily during the first week and 850 mg twice for the rest of the study period. In addition, they all received a 1 mg tablet of folate and 1 multivitamin tablet daily. (n=18) | Identical placebo dose was initiated. (n=22) | The “Revised 2003 consensus” diagnostic criteria of PCOS. |
| Vanky et al[11]       | Not reported.              | Norway   | RCT        | Women who were 18–45 y with PCOS had a singleton viable fetus shown on ultrasonography at gestational age between 5 and 12 wks. | Women who had alanine aminotransferase > 90 IU/L, serum creatinine concentration > 1.70 mg/dL, alcohol abuse, previously diagnosed diabetes mellitus or fasting serum glucose > 126 mg/dL, treatment with oral glucocorticoids, or use of drugs which interfere with metformin. | Metformin (metformin hydrochloride, Metformin, Weifa AS, Oslo, Norway) was given 500 mg twice during the first week and 1000 mg twice for the rest of the study period. In addition, they all received 0.8 mg folate and 1 multivitamin tablet daily. (n=135) | Identical placebo dose was initiated. | The “Revised 2003 consensus” diagnostic criteria of PCOS. |
| Salvesen et al[20]    | October 2000 to March 2003 | Norway   | RCT        | Women aged 18–40 y diagnosed with PCOS before conception and a single viable fetus was confirmed at gestational age 5–12 wks. | There was no description. | Metformin (metformin hydrochloride, Metformin, Weifa AS, Oslo, Norway) was given 850 mg once during the first week and 850 mg twice for the rest of pregnancy. In addition, all women received 1 mg folate and 1 multivitamin tablet daily. (n=18) | Identical placebo dose was initiated. (n=22) | The “Revised 2003 consensus” diagnostic criteria of PCOS. |
| Fougner et al[21]     | October 2000 to March 2003 | Norway   | RCT        | Women aged 18–40 y with PCOS before conception had a singleton viable fetus judged by ultrasonography at gestational age between 5 and 12 wks. | Women who had liver disease, s-creatinine > 130 mmol/L, alcohol abuse, previously diagnosed diabetes mellitus, fasting plasma glucose > 5.6 mmol/L, treatment with oral glucocorticoids or use of drugs known to interfere with metformin. | Metformin (metformin hydrochloride, Metformin®, Weifa AS, Norway) was given 425 mg once during the first week and 850 mg twice for the rest of the study period. In addition, they all received both a 1 mg tablet of folate and a multivitamin tablet daily. (n=18) | Identical placebo dose was initiated. (n=22) | The “Revised 2003 consensus” diagnostic criteria of PCOS. |
| Study                          | Period                  | Location     | Study type | Inclusion criteria                                      | Exclusion criteria                                      | Metformin (n)                                                                                     | Comparison (n)                                                                                     | Diagnostic criteria of PCOS                                                                 |
|-------------------------------|-------------------------|--------------|------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Morin-Papunen et al[22]       | January 2003 to December 2009 | Finland     | RCT        | Women who were aged 18–39 y with BMI > 19 kg/m² and diagnosed with PCOS. | There was no description.                                | Metformin (metformin hydrochloride depot tablets, Dilformin 500 mg; Leiras) was given 500 mg daily during the first week and up to 1500 mg in nonobese women and to 2000 mg daily in obese women up to the 12th week. (n=27) | Identical placebo dose was initiated. (n=34)                                                  | The “Revised 2003 consensus” diagnostic criteria of PCOS.                                   |
| Begum et al[23]               | June 2002 to December 2006 | Bangladesh   | P          | Women who had PCOS.                                     | There was no description.                                | Metformin was given 1500 mg daily for BMI > 29, 2000 mg daily for BMI 30–32 and 2500 mg daily for BMI > 32 until delivery. (n=29) | Identical metformin was discontinued at 8 wk of pregnancy. (n=30)                              | The “Revised 2003 consensus” diagnostic criteria of PCOS.                                   |
| Glueck et al[24]              | Not reported.           | Ohio         | P/R        | Women who had PCOS.                                     | Women who had serum creatinine level > 1.5 mg/dL, virilizing endocrinopathies, pituitary insufficiency, type 1 diabetes, and type 2 diabetes mellitus requiring pharmacologic therapy. In addition, women taking drugs affecting endogenous sex hormones or lipids and those taking valproic acid. | Metformin was given 2550 mg daily throughout pregnancy. (n=33) | Not taking metformin. (n=30)                                                               | The 1990 National Institutes of Health criteria.                                             |
| Khattab et al[25]             | April 2004 to January 2006 | Egypt        | P          | Women with PCOS had positive β-hCG and a viable single fetus on ultrasound. | Women who had hepatic or renal dysfunction, diabetes mellitus, persistent hyperprolactinemia, congenital adrenal hyperplasia, or pituitary insufficiency. | Metformin was given 1000–2000 mg daily throughout pregnancy according to individual BMI, WHR, manifestations of hyperandrogenism, HbA1c and tolerability of the patient to the side effects. In addition, vitamin B12 supplementation was given. (n=130) | Identical metformin was stopped at the confirmation of pregnancy. (n=80)                        | The “Revised 2003 consensus” diagnostic criteria of PCOS.                                   |
| Nawaz et al[21]               | January 2005 to December 2006 | Pakistan     | P          | Women who had PCOS.                                     | There was no description.                                | There was no description about the dose of Metformin. But metformin was given throughout the pregnancy. (n=45) | No use of Metformin. (n=26)                                                               | The “Revised 2003 consensus” diagnostic criteria of PCOS.                                   |
| Study                  | Period                  | Location     | Study type | Inclusion criteria                                                                 | Exclusion criteria                                                                                   | Metformin (n)                                                                                  | Comparison (n)                                                                 | Diagnostic criteria of PCOS |
|-----------------------|-------------------------|--------------|------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------|
| Nawaz and Rizwi[26]   | March 2005 to March 2008 | Pakistan     | P          | Women who had PCOS.                                                                  | Women who had other causes of miscarriages like antiphospholipid syndrome, cervical incompetence, genetic and autoimmune causes. | Metformin was given 500mg 3 times a day throughout the pregnancy. (n=119) | Metformin was either discontinued soon after confirmation of pregnancy. (n=78) | The “Revised 2003 consensus” diagnostic criteria of PCOS.                      |
| Khattab et al[27]     | August 2004 to January 2008 | Egypt        | P          | Women aged 18–40 y with PCOS had positive β-hCG and a visible single fetus on ultrasound | Women with PCOS had Patients hepatic or renal dysfunction, type 1 or type 2 DM, pituitary insufficiency, persistent hyperprolactinemia, and congenital adrenal hyperplasia | Metformin was given 1000–2000 mg daily throughout pregnancy according to individual BMI. (n=200) | Metformin was discontinued at the time of conception or at 8 weeks of pregnancy. (n=160) | The “Revised 2003 consensus” diagnostic criteria of PCOS.                      |
| Al-Biate et al[8]     | Between January 2008 and January 2011 | Ajman        | P          | Women aged 18–40 y with PCOS were diagnosed pregnancy with singleton fetus between gestational age between 5 and 12 wk. | Women who had other risk factors for miscarriage such as abnormal serum karyotyping for both parents; antiphospholipid syndrome, which was excluded by anticoagulant antibodies test; uterine anomalies on transvaginal ultrasound scanning; and diabetes mellitus by the oral glucose tolerance test. | Metformin was given 1000 mg daily throughout pregnancy. (n=56) | Metformin was discontinued once pregnancy started. (n=50) | The Rotterdam criteria (1996).                                             |
| Jakubowicz et al[28]  | January 1996 and June 2000 | Caracas, Venezuela | R          | Women with PCOS became pregnant.                                                    | There is no description.                                                                           | Metformin was given 1000–2000 mg daily throughout pregnancy. (n=65) | Metformin was stopped at the time of conception or during pregnancy. (n=31) | The “Revised 2003 consensus” diagnostic criteria of PCOS.                      |

BMI = body mass index, DM = diabetes mellitus, MET = metformin, P = prospective study, PCOS = polycystic ovary syndrome, R = retrospective study, WHR = waist/hip ratio, y = year.

The “Revised 2003 consensus” diagnostic criteria of PCOS: at least 2 of the 3 following criteria were fulfilled: polycystic ovaries, hyperandrogenism (clinical and/or biochemical), and oligo- and/or anovulation.

The 1990 National Institutes of Health criteria: oligomenorrhea or amenorrhea, biochemical or clinical hyperandrogenism, or polycystic ovaries on ultrasonography and exclusion of disorders that mimic PCOS.

The Rotterdam criteria, at least 2 of the following 3 criteria were fulfilled: presence of polycystic ovaries (> 9 subcapsular follicles of 10 mm by transvaginal ultrasonography), oligomenorrhea (length of menstrual cycles > 35 days or < 10 menstrual cycles/y), anovulation, and serum-free testosterone level > 2.5 nmol or clinical signs of hirsutism.
incidence of GDM and preeclampsia in women with PCOS. In women with PCOS, metformin use throughout pregnancy was associated with and might be responsible for a 9-fold reduction (30–3.44%) of GDM.\[23\] Concurrent with preceding researches, the prevalence of pregnancy complications such as GDM and PIH in our study was also dramatically declined. Moreover, researchers also found women with PCOS used metformin throughout pregnancy had a lower rate of CS and higher rate of VD. This new finding may add strength to the use of metformin throughout pregnancy.

There were researches noting metformin use in the first trimester had no adverse impact on fetal growth, including birth weight and head circumference.\[39,40\] Our result was in line with such a view on condition that the rate of IUGR was 21 out of 155 infants in the metformin group comparing with 35 out of 75 babies in the control group.

### Table 2

**Description of quality assessment of RCTs.**

| Study                  | Multi center | Randomization | Method to generate randomization clear and appropriate | Double blind | Methods for blinding appropriate | Methods of allocation concealment | Description of withdrawal or dropout | Completeness of follow-up (%) | Total score |
|------------------------|--------------|---------------|-------------------------------------------------------|--------------|----------------------------------|------------------------------------|-------------------------------------|------------------------------|--------------|
| Vanky et al\[19\]      | N$^\dagger$  | Y$^\ddagger$  | Y                                                     | Y            | Y                                | Y                                  | Y                                   | 95%                          | 7             |
| Vanky et al\[11\]      | Y            | Y             | Y                                                     | Y            | Y                                | Y                                  | Y                                   | 98.00%                      | 8             |
| Salvesen et al\[20\]   | N            | Y             | Y                                                     | Y            | Y                                | Y                                  | Y                                   | 95%                          | 7             |
| Fougner et al\[21\]    | Y            | Y             | Y                                                     | Y            | Y                                | Y                                  | Y                                   | 95%                          | 8             |
| Morin-Papunen et al\[22\] | Y            | Y             | Y                                                     | Y            | Y                                | Y                                  | Y                                   | 80.94%                      | 7             |

Score was assessed on the basis of the quality of randomization, double blinding and follow-up. Additionally, concealment of allocation was assessed as follows: 2 points, adequate method (central randomization, drug containers or opaque, sealed envelopes that were sequentially numbered and opened sequentially only after they had been irreversibly assigned to the participant); 0 points, no concealment of allocation or inadequate method or not described. Thus, the total score ranged from 0 (lowest quality) to 8 (highest quality).

$^\dagger$ Yes 1 point.

$^\ddagger$ No 0 point; follow-up ≥95% 1 point, follow-up <95% or unreported 0 point.

**Figure 2.** Meta-analysis of data about early pregnancy loss from 6 studies using a fixed-effect model. CI = confidence interval, OR = odds ratio.

**Figure 3.** Meta-analysis of data about preterm labor from 6 studies using a fixed-effect model. CI = confidence interval, OR = odds ratio.
There is accumulated evidence about the safety of continual use of metformin throughout pregnancy, but evidence of increased risk of congenital abnormalities has ever been reported.\(^{41}\) Coetzee and Jackson\(^{42}\) explored the effect of metformin in pregnant women and concluded that metformin did not lead to higher incidence of major congenital abnormalities. A retrospective study\(^{43}\) has examined the perinatal outcomes in metformin-treated and control pregnancies, and found that the rates of neonatal growth deficits, congenital defects, and neonatal unit admission were either comparable in both groups or less common in the metformin-treated group. Gilbert et al.\(^{44}\) also believed there was no evidence of an increased risk of major malformations when metformin was taken during the first trimester. Our analysis showed the rate of fetal malformation was comparative between the metformin group and the control group based on the limited data available, which was in accordance with pre-existing researches.

The half-life of metformin is 4 to 8 hours and it is excreted through the kidneys.\(^9\) The most common adverse effects of metformin include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, but they can be lightened or eliminated by taking the medication with food. The most frequent side-effects of metformin treatment were nausea and mild gastrointestinal symptoms.\(^{45}\) Less common adverse effects include vitamin B12 malabsorption, mild erythema, and rarely lactic acidosis.

![Figure 4](image-url) **Figure 4.** Meta-analysis of data about term delivery from 6 studies using a fixed-effect model. CI = confidence interval, OR = odds ratio.

![Figure 5](image-url) **Figure 5.** Meta-analysis of data about gestational diabetes mellitus from 8 studies using a random-effect model and a subgroup analysis was conducted. CI = confidence interval, OR = odds ratio.
Table 3

Secondary outcomes.

| Outcome                        | No. of studies | No. of MET group | No. of control group | OR     | 95% CI       | P     | I2 (%) |
|--------------------------------|----------------|------------------|----------------------|--------|--------------|-------|--------|
| Fetal malformation             | 3              | 5/277            | 4/109                | 1.11   | 0.30–4.13    | 0.88  | 0      |
| PIH                            | 4              | 28/403           | 51/282               | 0.22   | 0.13–0.38    | <0.0001 | 48     |
| IUGR                           | 2              | 21/155           | 35/75                | 0.17   | 0.08–0.33    | <0.0001 | 0      |
| VD                             | 4              | 218/370          | 195/333              | 1.13   | 0.81–1.56    | 0.48  | 0      |
| CS                             | 4              | 152/370          | 138/333              | 0.89   | 0.64–1.23    | 0.48  | 0      |
| Nausea or gastrointestinal discomfort | 2          | 6/35             | 6/43                 | 1.28   | 0.37–4.37    | 0.70  | 0      |

CI = internal confidence, CS = cesarean section, IUGR = intrauterine growth restriction, OR = odds ratio, PIH = pregnancy-induced hypertension, VD = vaginal.

P < 0.05 was considered to be of statistical significance.

If substantial heterogeneity was found (I2 > 25%), a random effects model was used.

acidosis.\textsuperscript{19,13} In this meta-analysis, 4 studies took folate and multivitamins as supplement and 1 study took only vitamin B12 as supplement, but data about the adverse effects deriving from lack of vitamins was still not enough. The side-effects of metformin treatment occurred in 6/35 in the metformin group versus 6/43 in the control group in our study, but the analysis yielded no statistical significance.

Overall, the strength of this study is stronger than any single study since the included primary studies are quite homogeneous. Among these, 5 RCTs were of high quality. The criteria of diagnosis of PCOS were clearly defined. This would undoubtedly enhance the persuasiveness of this study.

Nevertheless, several study limitations must be kept in mind when considering the generalizability of these data. First, there was a wide gap of the number of objects in the recruited trails, ranging from 40 to 360, which may weaken the strength of pooled studies. Then, data about infant outcomes, such as fetal malformation, IUGR, macrosomia, and neonatal death were limited, which possibly restricted the breadth of study. Besides, this meta-analysis showed no competence to detect metformin’s teratogenic potential. So such issues should be the focus in further investigations.

5. Conclusions

In conclusion, metformin treatment in pregnant women with PCOS throughout pregnancy could reduce the risk of EPL, preterm delivery, and increase the chance of term delivery sharply. As to pregnancy complications, continual use of metformin resulted in sharp reduction in the rates of GDM and PIH without increasing serious side effects. Based on the limited data, metformin was not teratogenic. Hence, it may be quite safe and beneficial to continue metformin treatment throughout pregnancy for both mothers and babies. In order to provide more convincing evidence for supporting the use of metformin in women with PCOS, more large-scale multicenter RCTs with long follow-up period are in urgent need. Of course, future studies should include not just EPL, preterm labor and PIH, but also fetal outcomes such as fetal malformation and fetal growth. Moreover, the optimal metformin dosage and regime also remain to be determined.

References

1. Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet (London, England) 1990;336:1141–4.
2. Watson H, Kiddly DS, Hamilton-Fairley D, et al. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage. Hum Reprod (Oxford, England) 1993;8:829–33.
3. Nawaz PH, Khalid R, Naur T, et al. Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? J Obstet Gynaecol Res 2008;34:832–7.
4. Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006;12:673–83.
5. Carmina E, Koyama T, Chang L, et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992;167:1807–12.
6. Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1163–74.
7. Moghetti P, Castello R, Negrin C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139–46.
8. Al-Biate MA. Effect of metformin on early pregnancy loss in women with polycystic ovary syndrome. Taiwanese J Obstet Gynecol 2015;54:266–9.
9. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50:81–98.
10. Marques P, Carvalho MR, Pinto L, et al. Metformin safety in the management of gestational diabetes. Endocr Pract 2014;20:1022–31.
11. Yank E, Stridsklev S, Heinstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab 2010;95:E448–e455.
12. Zheng J, Shan PF, Gu W. The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials. J Endocrinol Invest 2013;36:797–802.
13. HF P. Use of metformin during pregnancy for women with polycystic ovary syndrome. Open J Obstet Gynecol 2013;3:111–5.
[14] Zhuo Z, Wang A, Yu H. Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. J Diabetes Res 2014;2014:381231.

[15] Lautatzis ME, Goulis DG, Vrontakis M. Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. Metabolism 2013;62: 1522–34.

[16] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.

[17] Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–2.

[18] Egger M,Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629.

[19] Vanky E, Salvesen KA, Heimstad R, et al. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod (Oxford, England) 2004;19:1734–40.

[20] Salvesen KA, Vanky E, Carlsen SM. Metformin treatment in pregnant women with polycystic ovary syndrome—Is reduced complication rate mediated by changes in the uteroplacental circulation? Ultrasound Obstet Gynecol 2007;29:433–7.

[21] Fougner KJ, Vanky E, Carlsen SM. Metformin has no major effects on glucose homeostasis in pregnant women with PCOS: results of a randomized double-blind study. Scand J Clin Lab Invest 2008;68:771–6.

[22] Morin-Papunen L, Rantala AS, Unkila-Kallio I, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab 2012;97:1492–500.

[23] Begum MR, Khanam NN, Quadir E, et al. Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome. J Obstet Gynaecol Res 2009;35:282–6.

[24] Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002;77:320–5.

[25] Khattab S, Moshen IA, Foutouh IA, et al. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol 2006;22:680–4.

[26] Nawaz FH, Rizvi J. Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome. Gynecol Obstet Invest 2010;69:184–9.

[27] Khattab S, Moshen IA, Aboul Foutouh I, et al. Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. Gynecol Endocrinol 2011;27:789–93.

[28] Jakubowicz DJ, Juorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524–9.

[29] Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS): Hum Reprod (Oxford, England) 2004;19:41–7.

[30] Kyei-Mensah A, Zaidi J, Campbell S. Ultrasound diagnosis of polycystic ovary syndrome. Bailliere’s Clin Endocrinol Metab 1996;10:249–62.

[31] Haq F, Afzal O, Rizvi J. Clinical, biochemical and ultrasonographic features of infertile women with polycystic ovarian syndrome. J Coll Phys Surg Pakistan 2007;17:76–80.

[32] Balen AH, Dresner M, Scott EM, et al. Should obese women with polycystic ovary syndrome receive treatment for infertility? BMJ 2006;332:434–5.

[33] Ben-Haroush A, Yogev Y, Fisch B. Insulin resistance and metformin in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004;115:123–33.

[34] Ehrmann DA. Polycystic ovarian syndrome. N Engl J 2005;352:1223–36.

[35] Mikola M, Hilesmaa V, Halttunen M, et al. Obstetric outcome in women with polycystic ovary syndrome. Hum Reprod (Oxford, England) 2001;16:226–9.

[36] Glueck CJ, Goldenberg N, Streicher P, et al. The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin Pharmacother 2002;3:1557–68.

[37] Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 2002;3:1177–89.

[38] De Leo V, Musacchio MC, Pomboni P, et al. The administration of metformin during pregnancy reduces polycystic ovary syndrome-related gestational complications. Eur J Obstet Gynecol Reprod Biol 2011;157: 63–6.

[39] Bolton S, Cleary B, Walsh J, et al. Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. Eur J Pediatr 2009;168:203–6.

[40] Glueck CJ, Wang P, Goldenberg N, et al. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod (Oxford, England) 2002;17:2838–64.

[41] Glueck CJ, Goldenberg N, Wang P, et al. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod (Oxford, England) 2004;19: 510–21.

[42] Coetzee EJ, Jackson WP. Oral hypoglycaemics in the first trimester and fetal outcome. South African Med J 1984;65:635–7.

[43] Diamanti-Kandarakis E, Christakou CD, Kandarakis E, et al. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010;162:193–212.

[44] Gilbert G, Valos M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril 2006;86:658–63.

[45] Hall GM, Nicholton G. Current therapeutic drugs for type 2 diabetes, still useful after 50 years? Anesth Analg 2009;108:1727–30.